Key Takeaways
- Biotalys has entered a strategic partnership with 21st.BIO to accelerate biocontrol manufacturing.
- The collaboration leverages precision fermentation to reduce costs and support large-scale production.
- The agreement strengthens the AGROBODY platform and supports EVOCA™ NG commercialization.
- Biotalys will conclude its prior collaboration with Novonesis as part of the transition.
- The company confirmed cash runway into May 2026 while evaluating additional financing options.
Biotalys Strengthens AGROBODY Platform Through Precision Fermentation Partnership
Biotalys (Euronext: BTLS), a developer of protein-based biocontrol solutions, has announced a strategic partnership with 21st.BIO, a Danish precision fermentation technology company. The collaboration is designed to accelerate and scale the production of Biotalys’ AGROBODY agricultural biocontrol products at commercially competitive costs.
Under the agreement, Biotalys will leverage 21st.BIO’s proprietary precision fermentation platform, which is powered by production strains refined over more than four decades and proven in commercial applications. Part of the technology is licensed from Novonesis, building on earlier work conducted jointly by Biotalys and Novonesis.
Biotalys Expands Manufacturing Options for Protein-Based Biocontrols
The partnership is expected to expand process development options and support efficient, large-scale manufacturing of Biotalys’ protein-based biocontrol solutions. According to the company, strengthening manufacturing capabilities is a key step toward commercialization of its lead product and broader pipeline.
“This partnership marks an important strategic step in strengthening the technical backbone of our AGROBODY platform,” said Kevin Helash, CEO of Biotalys. “By combining 21st.BIO’s proven fermentation expertise with our own innovation in protein-based biocontrols, we are reinforcing the foundation needed to support a growing and differentiated product portfolio.”
Helash added that collaboration with Novonesis and its relationship with 21st.BIO played a critical role in advancing Biotalys’ first commercial product, EVOCA™ NG, toward market readiness.
Precision Fermentation to Support Commercial Scale-Up
Focus on Cost, Speed, and Reliability
21st.BIO’s platform is designed to translate lab-scale biotech innovations into industrial-scale production more quickly and with reduced risk. The company stated that its role in the partnership is to help Biotalys lower production costs and accelerate time to market.
“21st.BIO was founded on the ambition to bring promising lab-scale innovation to reliable, cost-effective, industrial-scale biotech production,” said Thomas Schmidt, Co-founder and CEO of 21st.BIO. “Our collaboration will ensure that protein-based biocontrols like EVOCA NG become a sustainable and cost-effective option for growers globally.”
Biotalys noted that the agreement positions its products as scalable alternatives within the crop protection market, supporting safer and more sustainable agricultural practices.
Biotalys Commercialisation and Funding Outlook
In line with the transition to the new partnership, Biotalys and Novonesis will conclude their collaboration. Biotalys stated that it is actively engaging with manufacturing and distribution partners globally to finalize its commercialization strategy.
The company expects to have key arrangements in place well ahead of the planned launch of EVOCA NG, subject to regulatory approval. Registration is currently anticipated for 2028–29 in the United States and 2029–30 in the European Union.
Biotalys also confirmed that its current cash runway extends into May 2026, as previously announced. To support the next phase of development and commercialization, the company is evaluating additional financing options, including potential equity investment from institutional investors, to fund EVOCA NG and advance its broader AGROBODY biocontrol portfolio.
4 Comments